Quintiles is one of the most aggressive CRO in the world, I was
impressed by its India strategy , when it entered Indian market with a bang in 2001
and within some years had grown to more than 100 times in Indian operations
compared to other CRO’s who later came and opened their operations in India
beside local players, earlier it had services related from pre clinical to post
marketing trials, but some 5-6 years back it sold its preclinical operations
and then later diversified itself into genomic studies and recently with it has
diversified itself as sole partners from genomic studies to clinical to
regulatory filing.
It has strong team of more than 100 people in New York which caters to
its overall strategic decisions and other portfolio diversification. If I look
into their strategy of expansion into countries around the world, rather than
forming very big alliances it opened its shop for business on its own and has
been the pioneer or the early entrants in all the major emerging markets. In Russian
federation though it formed JV and then further buy out
Earlier it was public company which became private after some years, as
the new CEO has joined industry analysts believe that it will go public....we
need to watch if it’s going to be a public company.....
"I view the fact that they have a new CEO now as potentially a sign
that they're preparing their next leg of growth or next strategy, which could
include an IPO," Moody's analyst Jessica Gladstone told Bloomberg.
"An IPO could also be a way to reduce leverage and an exit strategy for
the owners."
Read more:
PS: I have been watching Quintiles for more
then 5-6 years from the time I have joined consultancy industry thus these are
my viewpoints
No comments:
Post a Comment